Upstream Bio Announces Addition to Russell 2000® Index
Upstream Bio (Nasdaq: UPB) announced its upcoming addition to the Russell 2000® Index, effective December 23, 2024, as part of the fourth quarter IPO additions. The Russell 2000® Index, which measures the performance of the U.S. small-cap equity market segment, is widely used by investment managers and institutional investors for index funds and investment strategy benchmarking. The index represents approximately 10% of the total market capitalization of the Russell 3000® Index, including about 2,000 of the smallest securities. Notably, approximately $10.5 trillion in assets are benchmarked against Russell US indexes as of December 2023.
Upstream Bio (Nasdaq: UPB) ha annunciato la sua prossima inclusione nell'Indice Russell 2000®, a partire dal 23 dicembre 2024, come parte delle aggiunte alle IPO del quarto trimestre. L'Indice Russell 2000®, che misura la performance del segmento di mercato azionario statunitense a piccola capitalizzazione, è ampiamente utilizzato da gestori di investimento e investitori istituzionali per fondi indicizzati e benchmarking delle strategie di investimento. L'indice rappresenta circa il 10% della capitalizzazione di mercato totale dell'Indice Russell 3000®, comprendendo circa 2.000 dei titoli più piccoli. È significativo notare che circa $10,5 trilioni in attività sono confrontati con gli indici Russell USA a dicembre 2023.
Upstream Bio (Nasdaq: UPB) anunció su próxima inclusión en el Índice Russell 2000®, a partir del 23 de diciembre de 2024, como parte de las adiciones de IPO del cuarto trimestre. El Índice Russell 2000®, que mide el rendimiento del segmento del mercado de acciones de pequeña capitalización en EE. UU., es ampliamente utilizado por gestores de inversión e inversores institucionales para fondos indexados y la referencia de estrategias de inversión. El índice representa aproximadamente el 10% de la capitalización de mercado total del Índice Russell 3000®, incluyendo alrededor de 2.000 de los valores más pequeños. Es notable que aproximadamente $10.5 billones en activos están referenciados a los índices Russell de EE. UU. a diciembre de 2023.
업스트림 바이오 (Nasdaq: UPB)는 러셀 2000® 지수에 2024년 12월 23일부터 추가될 것이라고 발표했습니다. 이는 4분기 IPO 추가의 일환입니다. 러셀 2000® 지수는 미국의 소형주 주식 시장 세그먼트의 성과를 측정하며, 투자 매니저와 기관 투자자들이 인덱스 펀드 및 투자 전략 벤치마킹을 위한 목적으로 널리 사용됩니다. 이 지수는 러셀 3000® 지수의 총 시장 자본화의 약 10%를 차지하며, 약 2,000개의 가장 작은 증권을 포함합니다. 주목할 점은 2023년 12월 기준으로 약 10.5조 달러의 자산이 러셀 미국 인덱스에 대해 벤치마킹되고 있다는 것입니다.
Upstream Bio (Nasdaq: UPB) a annoncé son ajout prochain à l'Indice Russell 2000®, effectif le 23 décembre 2024, dans le cadre des ajouts d'IPO du quatrième trimestre. L'Indice Russell 2000®, qui mesure la performance du segment du marché des actions de petite capitalisation aux États-Unis, est largement utilisé par les gestionnaires d'investissement et les investisseurs institutionnels pour les fonds indiciels et le benchmarking des stratégies d'investissement. L'indice représente environ 10 % de la capitalisation boursière totale de l'Indice Russell 3000®, incluant environ 2.000 des titres les plus petits. Il est notable qu'environ 10,5 trillions de dollars d'actifs sont référencés par rapport aux indices Russell des États-Unis en décembre 2023.
Upstream Bio (Nasdaq: UPB) hat seine bevorstehende Aufnahme in den Russell 2000® Index zum 23. Dezember 2024 angekündigt, als Teil der IPO-Zugänge im vierten Quartal. Der Russell 2000® Index, der die Leistung des amerikanischen Marksegment für Aktien mit kleiner Marktkapitalisierung misst, wird von Vermögensverwaltern und institutionellen Anlegern häufig für Indexfonds und Benchmarking von Anlagestrategien verwendet. Der Index repräsentiert etwa 10 % der Gesamtkapitalisierung des Russell 3000® Index, einschließlich etwa 2.000 der kleinsten Wertpapiere. Bemerkenswert ist, dass bis Dezember 2023 etwa 10,5 Billionen Dollar an Vermögenswerten gegen die Russell-US-Indizes benchmarked werden.
- Inclusion in Russell 2000® Index increases visibility to institutional investors
- Potential for increased trading volume and liquidity due to index fund inclusion
- Access to $10.5 trillion benchmark-linked investment pool
- None.
Insights
The addition of Upstream Bio to the Russell 2000® index represents a significant milestone that could enhance the company's visibility and trading liquidity. With approximately
Small-cap biotech companies often benefit substantially from Russell 2000® inclusion, as it provides validation of their market position and can attract additional analyst coverage. For Upstream Bio, this comes at a important time as they advance their clinical-stage pipeline in inflammatory diseases. The inclusion could improve their access to capital markets and potentially lower their cost of capital for future fundraising efforts.
WALTHAM, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that the Company will be added to the Russell 2000® index as part of the planned fourth quarter initial public offering (IPO) additions effective at the open of the U.S. equity markets on December 23, 2024.
Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. According to the data as of the end of December 2023, about
The Russell 2000® Index measures the performance of the small-cap segment of the US equity market. The Russell 2000® Index is a subset of the Russell 3000® Index representing approximately
About Upstream Bio
Upstream Bio is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. The Company is developing verekitug, the only known antagonist currently in clinical development that targets the receptor for thymic stromal lymphopoietin, a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases. The Company has advanced this highly potent monoclonal antibody into separate Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and plans to initiate development in chronic obstructive pulmonary disease. Upstream Bio’s team is committed to maximizing verekitug’s unique attributes to address the substantial unmet needs for patients underserved by today’s standard of care. To learn more, please visit www.upstreambio.com.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. These statements may be identified by words such as "aims," "anticipates," "believes," “continue,” "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," “predict,” “project,” "seeks," “should,” “target,” "will" and variations of these words or similar expressions. Any statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include, without limitation, express or implied statements regarding the expected addition of the Company to the Russell 2000® index. Any forward-looking statements in this press release are based on Upstream’s current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Readers are cautioned that actual results, levels of activity, safety, efficacy, performance or events and circumstances could differ materially from those expressed or implied in Upstream’s forward-looking statements due to a variety of risks and uncertainties, which include, without limitation, risks and uncertainties related to: Upstream’s ability to advance verekitug through clinical development, and to obtain regulatory approval of and ultimately commercialize verekitug on the expected timeline, if at all; the initiation, timing, progress and results of clinical trials; Upstream’s ability to fund its development activities and achieve development goals; Upstream’s dependence on third parties to conduct clinical trials and manufacture verekitug, and commercialize verekitug, if approved; Upstream’s ability to attract, hire and retain key personnel, and protect its intellectual property; Upstream’s financial condition and need for substantial additional funds in order to complete development activities and commercialize verekitug, if approved; regulatory developments and approval processes of the U.S. Food and Drug Administration and comparable foreign regulatory authorities; Upstream’s competitors and industry; and other risks and uncertainties described in Upstream’s current and future filings with the SEC, including those described from time to time under the caption “Risk Factors.” Upstream explicitly disclaims any obligation or undertaking to update any forward-looking statements contained herein to reflect any change in its expectations or any changes in events, conditions or circumstances on which any such statement is based except to the extent required by law, and claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.
FAQ
When will Upstream Bio (UPB) be added to the Russell 2000 Index?
What is the significance of UPB joining the Russell 2000 Index?
How many companies are included in the Russell 2000 Index with UPB?
What is the total asset value benchmarked against Russell US indexes that UPB will be part of?
